CN104474173A - Medicine for treating facial nerve paralysis - Google Patents

Medicine for treating facial nerve paralysis Download PDF

Info

Publication number
CN104474173A
CN104474173A CN201410677978.1A CN201410677978A CN104474173A CN 104474173 A CN104474173 A CN 104474173A CN 201410677978 A CN201410677978 A CN 201410677978A CN 104474173 A CN104474173 A CN 104474173A
Authority
CN
China
Prior art keywords
medicine
radix
decoction
processed
folium artemisiae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410677978.1A
Other languages
Chinese (zh)
Other versions
CN104474173B (en
Inventor
李镇荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410677978.1A priority Critical patent/CN104474173B/en
Publication of CN104474173A publication Critical patent/CN104474173A/en
Application granted granted Critical
Publication of CN104474173B publication Critical patent/CN104474173B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Insects & Arthropods (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine for treating facial nerve paralysis. The medicine is an agent prepared from the raw materials such as radix astragali preparata, uncaria, white paeony root, peach kernel, stiff silkworm, red flower, ligusticum wallichii, earthworm, angelica sinensis, asarum, rhizoma typhonii, folium artemisiae argyi and scorpion. The medicine can be processed into decoction, tablets, pills, powder, capsules and other dosage forms. The medicine complies with the principle of combining differentiation of disease and dialectical treatment, both symptoms and root causes are treated, the curative effect is mutually increased, the formula is strict, the division is clear, so that the drug effect directly reaches lesions. According to the application in many years, the cure rate can be 87 percent, the total effective rate is 97 percent, and the medicine is obvious in curative effect and does not have any toxic or side effect.

Description

One treats prosopoplegic medicine
Technical field
The invention belongs to dyskinesia field, particularly relate to one and treat prosopoplegic medicine.
Background technology
Facial paralysis is a kind of disease common in department of neurology, and not by the restriction at age, PD is rapid, has had a strong impact on the orthobiosis of patient.Common sympton is facial hemiparalysis, face spasm, babble, eyes closed difficulty, shed tears with eyes, masticatory atonia, dysphagia, sialorrhea, when drinking water, the corners of the mouth leaks, during feed, food debris is often stranded in the tooth volume gap of disease side, and has saliva to drop down from sick side, nasal obstruction, tinnitus, headache, trigeminal neuralgia, the toothache that facial neuritis causes.At present, the main antiinflammatory of Western medicine, detumescence, blood vessel dilating medicine is treated, as with hormone, vitamins, as Drug therapys such as the year with nitric acid scholar, cortisone acetate, VB12, therapeutic effect is not good, easily develops immunity to drugs, and side effect is very big, cure rate is not high, so that invalid for a long time, can only take stopgap measures, can not effect a permanent cure, finally leave sequela, bring great stress to patient.
The traditional Chinese medical science is thought, facial paralysis belongs to the category of apoplexy, is commonly called as facial paralysis, facial paralysis, wapperijaw wind, and the generation of primary disease mainly face experiences ailment said due to cold or exposure, obstruction of collateral caused by windphlegm, and meridians are obstructed, and cause facial qi-blood circulating obstacle, and meridians lose supports, therefore causes facial nerve paralysis.The traditional Chinese medical science then more adopts QIANZHENGSAN orally taken for curing, and because medicine time is long, curative effect is not high, and effect is undesirable; In addition, testing room plaster, acupuncture is also traditional treatment means, though effective, the cycle is long, and cure rate is low, neither desirable.
Summary of the invention
For prior art, the invention discloses the prosopoplegic medicine of a kind for the treatment of completely newly, there is the advantages such as therapeutic effect is good, cure rate is high, no sequel.
Medicine of the present invention is the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 20 ~ 42, Ramulus Uncariae Cum Uncis 10 ~ 30, the Radix Paeoniae Alba 10 ~ 30, Semen Persicae 7 ~ 17, Bombyx Batryticatus 7 ~ 17, Flos Carthami 7 ~ 17, Rhizoma Chuanxiong 7 ~ 17, Pheretima 7 ~ 17, Radix Angelicae Sinensis 6 ~ 15, Herba Asari 3 ~ 10, Rhizoma Typhonii 3 ~ 10, Folium Artemisiae Argyi 3 ~ 10, Scorpio 3 ~ 10.
As a kind of preferred implementation, the weight proportion of each raw material is: Radix Astragali Mongolici (processed) 25 ~ 36, Ramulus Uncariae Cum Uncis 14 ~ 25, the Radix Paeoniae Alba 14 ~ 25, Semen Persicae 9 ~ 15, Bombyx Batryticatus 9 ~ 15, Flos Carthami 9 ~ 15, Rhizoma Chuanxiong 9 ~ 15, Pheretima 9 ~ 15, Radix Angelicae Sinensis 8 ~ 12, Herba Asari 5 ~ 8, Rhizoma Typhonii 5 ~ 8, Folium Artemisiae Argyi 4 ~ 8, Scorpio 4 ~ 8.
As a kind of preferred implementation, the weight proportion of each raw material is: Radix Astragali Mongolici (processed) 30, Ramulus Uncariae Cum Uncis 20, the Radix Paeoniae Alba 20, Semen Persicae 12, Bombyx Batryticatus 12, Flos Carthami 12, Rhizoma Chuanxiong 12, Pheretima 12, Radix Angelicae Sinensis 10, Herba Asari 6, Rhizoma Typhonii 6, Folium Artemisiae Argyi 6, Scorpio 6.
Above-mentioned raw material of Chinese medicine is made medicinal preparation for oral administration according to a conventional method, namely described on pharmaceutics decoction, tablet, pill, powder, capsule etc.
The concrete preparation method of medicine decoction of the present invention and capsule is as follows:
Take each crude drug of above-mentioned weight proportion, rinse well with water, decoct with water 2 ~ 4 times, each decoction adds the water of crude drug gross weight 1.5 ~ 6 times, decocts 15 ~ 20 minutes, merges each decocting liquid, and remove slag dress bag after filtration, namely obtains decoction; By the decocting liquid after filtering through being condensed into relative density 1.18 ~ 1.27(50 DEG C) thick paste, dry, be ground into fine powder, make capsule in incapsulating; The customary adjuvant adding pill agent obtains pill; The customary adjuvant adding film-making agent obtains tablet; Add lyophilized powder and obtain injection.
As a kind of preferred implementation, also can by each crude drug of above-mentioned weight proportion, rinse well with water, various medicines except Ramulus Uncariae Cum Uncis are decocted with water 5 ~ 10 minutes, then adds Ramulus Uncariae Cum Uncis continuation decoction 10 ~ 20 minutes, repeat decoction 3 times, each decoction adds the water of crude drug gross weight 1.5 ~ 6 times, merge the decocting liquid of 3 times, remove slag dress bag after filtration, namely obtains decoction; By the decocting liquid after filtering through being condensed into relative density 1.18 ~ 1.27(50 DEG C) thick paste, dry, be ground into fine powder, make capsule in incapsulating.
Radix Astragali Mongolici (processed) invigorating QI to consolidate the body surface resistance, QI invigorating invigorating middle warmer, promoting pus discharge and tissue regeneration strengthening in the present invention; Ramulus Uncariae Cum Uncis heat clearing away suppressing the hyperactive liver, relieving spasm by subduing liver-wind, have good opsonic action to facial paralysis, reaches the optimum efficiency of suppressing the hyperactive liver to relieve the wind syndrome, removing obstruction in the collateral to relieve pain, giving consideration to both the incidental and fundamental, easing the affected liver yin nourishing with the Scorpio of being longer than endogenous wind stopping, the Radix Paeoniae Alba compatibility of being good at restraining; The promoting the circulation of blood of Semen Persicae blood stasis dispelling, has good curative effect with Radix Angelicae Sinensis, Flos Carthami, Rhizoma Chuanxiong, the facial paralysis of Pheretima compatibility to stagnation of QI-blood type; Bombyx Batryticatus spasmolytic, calmness, fresh breeze heat, have with Ramulus Uncariae Cum Uncis, Herba Asari compatibility wind heat diseases such as treating wind heat infantile convulsion is twitched, headache due to pathogenic wind-heat, contribute to the conditioning of patient's heart, liver, spleen, lung meridian network with Rhizoma Typhonii, Rhizoma Chuanxiong compatibility, and playing altogether dispels the wind treats the effect of numbness; Flos Carthami promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing, the property of joining Semen Persicae, the power of Rhizoma Chuanxiong removing blood stasis, pungent loose temperature logical is splendid, reaches effect of dysmenorrhea dissipating blood stasis, removing blood stasis circulation of qi promoting; Rhizoma Chuanxiong blood-activating and qi-promoting, wind-expelling pain-stopping, Herba Asari also has expelling wind and cold pain relieving, the sensible effect of warming the lung to resolve fluid-retention, and slightly poisonous, and Rhizoma Chuanxiong and Herba Asari compatibility play the effect of expelling wind and activating blood circulation cold expelling altogether, add that Rhizoma Chuanxiong is nursed one's health Liver Channel, and curative effect plays better; Rhizoma Typhonii cold-dispelling, by cold-damp, only Ching pain relieving, to facial hemiparalysis disease in facial paralysis, there is excellent effect with the Scorpio compatibility wind relieving convulsion that falls apart; Folium Artemisiae Argyi joins the Radix Paeoniae Alba, Radix Angelicae Sinensis to spleen, lung, kidney three channels and network vessels regulations, reaches dispersing cold for relieving pain effect.In the present invention, every Chinese medicine cooperatively interacts coordination, and mutually promote curative effect, prescription is rigorous, and the division of labor clearly makes drug effect go directly focus.The present invention by the dredging of health meridians, the conditioning of negative and positive deficiency and excess, reaches the object strengthening patient's autoimmune function, makes the treatment that facial paralysis obtains fundamentally.
Drug therapy rheumatic lumbocrural pain of the present invention pain is not only effective, and can effect a radical cure, and not only takes stopgap measures, and effects a permanent cure, little to the side effect of human body, and effect is far super in other/Western medicine.
Detailed description of the invention
Now the specific embodiment of the present invention and curative effect are described in further detail in conjunction with the embodiments.
Embodiment 1
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 20g, Ramulus Uncariae Cum Uncis 10g, Radix Paeoniae Alba 10g, Semen Persicae 7g, Bombyx Batryticatus 7g, Flos Carthami 7g, Rhizoma Chuanxiong 7g, Pheretima 7g, Radix Angelicae Sinensis 6g, Herba Asari 3g, Rhizoma Typhonii 3g, Folium Artemisiae Argyi 3g, Scorpio 3g, by above-mentioned each crude drug, rinse well with water, decoct with water 2 times, each decoction adds the water of crude drug gross weight 6 times, decoct 20 minutes, merge the decocting liquid of 2 times, remove slag dress bag after filtration, namely obtains decoction.
Embodiment 2
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 42g, Ramulus Uncariae Cum Uncis 30g, Radix Paeoniae Alba 30g, Semen Persicae 17g, Bombyx Batryticatus 17g, Flos Carthami 17g, Rhizoma Chuanxiong 17g, Pheretima 17g, Radix Angelicae Sinensis 15g, Herba Asari 10g, Rhizoma Typhonii 10g, Folium Artemisiae Argyi 10g, Scorpio 10g, by above-mentioned each crude drug, rinse well with water, decoct with water 4 times, each decoction adds the water of crude drug gross weight 5 times, decoct 18 minutes, merge the decocting liquid of 4 times, remove slag dress bag after filtration, namely obtains decoction.
Embodiment 3
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 25g, Ramulus Uncariae Cum Uncis 14g, Radix Paeoniae Alba 14g, Semen Persicae 9g, Bombyx Batryticatus 9g, Flos Carthami 9g, Rhizoma Chuanxiong 9g, Pheretima 9g, Radix Angelicae Sinensis 8g, Herba Asari 5g, Rhizoma Typhonii 5g, Folium Artemisiae Argyi 4g, Scorpio 4g, by above-mentioned each crude drug, rinse well with water, decoct with water 4 times, each decoction adds the water of crude drug gross weight 1.5 times, decoct 15 minutes, merge the decocting liquid of 4 times, removing slag through being condensed into relative density is after filtration 1.27(50 DEG C) thick paste, dry, be ground into fine powder, capsule is made in incapsulating.
Embodiment 4
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 36g, Ramulus Uncariae Cum Uncis 25g, Radix Paeoniae Alba 25g, Semen Persicae 15g, Bombyx Batryticatus 15g, Flos Carthami 15g, Rhizoma Chuanxiong 15g, Pheretima 15g, Radix Angelicae Sinensis 12g, Herba Asari 8g, Rhizoma Typhonii 8g, Folium Artemisiae Argyi 8g, Scorpio 8g, by above-mentioned each crude drug, rinse well with water, decoct with water 3 times, each decoction adds the water of crude drug gross weight 3 times, decoct 18 minutes, merge the decocting liquid of 3 times, removing slag through being condensed into relative density is after filtration 1.20(50 DEG C) thick paste, dry, be ground into fine powder, the customary adjuvant adding pill agent obtains pill.
Embodiment 5
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 30g, Radix Angelicae Sinensis 10g, Ramulus Uncariae Cum Uncis 20g, Semen Persicae 12g, Bombyx Batryticatus 12g, Herba Asari 6g, Radix Paeoniae Alba 20g, Flos Carthami 12g, Rhizoma Typhonii 6g, Rhizoma Chuanxiong 12g, Pheretima 12g, Folium Artemisiae Argyi 6g, Scorpio 6g, by above-mentioned each crude drug, rinse well with water, various medicines except Ramulus Uncariae Cum Uncis are decocted with water 10 minutes, add Ramulus Uncariae Cum Uncis again and continue decoction 10 minutes, repeat decoction 3 times, each decoction adds the water of crude drug gross weight 4 times, merge the decocting liquid of 3 times, removing slag through being condensed into relative density is after filtration 1.25(50 DEG C) thick paste, dry, be ground into fine powder, the customary adjuvant adding film-making agent obtains tablet.
Embodiment 6
One treats prosopoplegic medicine, the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 30g, Radix Angelicae Sinensis 10g, Ramulus Uncariae Cum Uncis 20g, Semen Persicae 12g, Bombyx Batryticatus 12g, Herba Asari 6g, Radix Paeoniae Alba 20g, Flos Carthami 12g, Rhizoma Typhonii 6g, Rhizoma Chuanxiong 12g, Pheretima 12g, Folium Artemisiae Argyi 6g, Scorpio 6g, by above-mentioned each crude drug, rinse well with water, various medicines except Ramulus Uncariae Cum Uncis are decocted with water 5 minutes, add Ramulus Uncariae Cum Uncis again and continue decoction 20 minutes, repeat decoction 3 times, each decoction adds the water of crude drug gross weight 3 times, merge the decocting liquid of 3 times, removing slag through being condensed into relative density is after filtration 1.18(50 DEG C) thick paste, dry, be ground into fine powder, add lyophilized powder and obtain injection.
In order to investigate the prosopoplegic clinical efficacy of Drug therapy of the present invention further, 200 routine facial paralysis Diseases are selected to carry out clinical observation on the therapeutic effect.
1. case-data
Observe case totally 200 examples, patient is outpatient service and the admissions office patient of certain academy of traditional Chinese medicine, its single-blind randomized is divided into treatment group and matched group 2 groups, often organizes each 100 examples.In age 25-70 year in treatment group, the mean age is 47.5 years old, the course of disease 1 month ~ 15 years, average 1.2 years; In age 24-72 year in matched group, the mean age is 47.2 years old, the course of disease 1 month ~ 15 years, average 1.1 years.Two groups are compared at age, the course of disease, coincident with severity degree of condition and accompanying diseases etc., have comparability.
2. diagnostic criteria
Facial paralysis patient is divided into peripheral facial paralysis and central facial palsy, and the former is mostly agnogenio, with cold, wind, viral infection is relevant, may because of affected part nerve conduction imbalance caused by, the complication that the latter causes for cerebrovas-cularaccident, shows as disease side surface part histrionic palsy, and volume stricture of vagina disappears or shoals, can not frown by the volume of wrinkling, palpebral fissure can not close or dysraphism, and when examination is closed one's eyes, paralysis branch hole ball rotates upward, expose white sclera, claim bell's phenomenon.Sick side nasolabial fold shoals, ptosis of labial angle, and Face and cheek is led to strong side, closes one's eyes, grinningly, drum cheek, the action such as to whistle be malfunctioning, or can not complete completely.Because of buccinator muscle paralysis, food is easily stranded between the tooth cheek of disease side.Lacrimal point turns up with lower eyelid, makes tear can not normal absorption and cause excessive.As invade and drum bundle is neural time, there will be 2/3 dysgeusia before tongue.
3. Therapeutic Method.
3.1 treatment groups: give tcm therapy, take decoction of the present invention or capsule, decoction: every agent 200mL, and every day early, evening 2 times is oral, each 200 mL; Capsule: every capsules contains Chinese medicine powder 0.12g of the present invention, morning every day, evening 2 times, each 2 ~ 8; Capsules/tablets/pill: every capsules/sheet/ball contains Chinese medicine powder 0.12g of the present invention, morning every day, evening 2 times, each 2 ~ 8; Injection: often prop up containing Chinese medicine powder 0.8g of the present invention, every day each one sooner or later; Diet is pungent, peppery, sour, cold, greasy, wine tea etc., and within 15 days, be a course for the treatment of, general 3-10 will significantly improve a course for the treatment of, and consumption can make the appropriate adjustments according to patient age, body weight, the type and the order of severity etc. of disease for the treatment of.
3.2 matched groups: give conventional treatment, as antiinflammatory, detumescence, blood vessel dilating medicine is treated, and as with hormone, vitamin, and coordinates traction treatment and acupuncture and moxibustion treatment to carry out auxiliary treatment, diet is pungent, peppery, sour, cold, greasy, wine tea etc.
4. observation index.
4.1 curative effect index patient subjective symptomss, record respectively to the symptom before and after patient treatment, pass judgment on therapeutic effect according to criterion of cure, effectively standard.
The general health check-up project of 4.2 safety indexes (body temperature, breathing, pulse, blood pressure), hematuria stool routine, darling renal function inspection etc., to begin a project all before medication and terminate rear each inspection each course for the treatment of once, observe untoward reaction at any time.
5 criterions of therapeutical effect and therapeutic outcome.
5.1 standards determine following standard with reference to " clinical disease diagnosis is according to curing improvement standard ": criterion of cure is the complete transference cure of patient, and upper and lower catacleisis is good, facial muscle functional rehabilitation; Effective standard is that the state of an illness is clearly better, and volume stricture of vagina recovers, and upper and lower catacleisis strength is weak, visible Ipsilateral slight ptosis of labial angle when laughing at of crying, and facial muscle groups contractile motion is slightly poor; Null criterion is that symptom and lab testing are without obvious change.
5.2 liang of group patient comparitive study, in table 1
From table 1, in the routine patient for the treatment of group 100, cure 87 examples, effective 10 examples, invalid 3 examples, total effective rate is 97%; In the routine patient of matched group 100, cure 35 examples, effective 23 examples, invalid 42 examples, total effective rate is 58%.
Table 1 liang group patient comparitive study.
Group Cure Effectively Invalid Total effective rate
Treatment group (100) 87 10 3 97%
Matched group (100) 35 23 42 58%
5.3 safety indexes are observed
Before and after this clinical observation treatment, two groups of general health check-up projects of patient, the inspection of hematuria stool routine, cardiac inspections etc. have no significant change.Viewing duration, two groups there is not serious adverse events during this clinical observation, and before and after treatment, hepatic and renal function and routine blood test index of correlation are all without significant difference.
Visible, medicine of the present invention more can significantly improve prosopoplegic curative effect than traditional remedies, and there is not side effect, and patient compliance is good, has actual clinical meaning.

Claims (3)

1. treat a prosopoplegic medicine, it is characterized in that it is the medicament be made up of the raw material of following weight proportioning: Radix Astragali Mongolici (processed) 20 ~ 42, Ramulus Uncariae Cum Uncis 10 ~ 30, the Radix Paeoniae Alba 10 ~ 30, Semen Persicae 7 ~ 17, Bombyx Batryticatus 7 ~ 17, Flos Carthami 7 ~ 17, Rhizoma Chuanxiong 7 ~ 17, Pheretima 7 ~ 17, Radix Angelicae Sinensis 6 ~ 15, Herba Asari 3 ~ 10, Rhizoma Typhonii 3 ~ 10, Folium Artemisiae Argyi 3 ~ 10, Scorpio 3 ~ 10.
2. the prosopoplegic medicine for the treatment of as claimed in claim 1, is characterized in that the weight proportion of wherein each raw material is: Radix Astragali Mongolici (processed) 25 ~ 36, Ramulus Uncariae Cum Uncis 14 ~ 25, the Radix Paeoniae Alba 14 ~ 25, Semen Persicae 9 ~ 15, Bombyx Batryticatus 9 ~ 15, Flos Carthami 9 ~ 15, Rhizoma Chuanxiong 9 ~ 15, Pheretima 9 ~ 15, Radix Angelicae Sinensis 8 ~ 12, Herba Asari 5 ~ 8, Rhizoma Typhonii 5 ~ 8, Folium Artemisiae Argyi 4 ~ 8, Scorpio 4 ~ 8.
3. the prosopoplegic medicine for the treatment of as claimed in claim 1, is characterized in that the weight proportion of wherein each raw material is: Radix Astragali Mongolici (processed) 30, Ramulus Uncariae Cum Uncis 20, the Radix Paeoniae Alba 20, Semen Persicae 12, Bombyx Batryticatus 12, Flos Carthami 12, Rhizoma Chuanxiong 12, Pheretima 12, Radix Angelicae Sinensis 10, Herba Asari 6, Rhizoma Typhonii 6, Folium Artemisiae Argyi 6, Scorpio 6.
CN201410677978.1A 2014-11-24 2014-11-24 A kind of medicine for treating facioplegia Active CN104474173B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410677978.1A CN104474173B (en) 2014-11-24 2014-11-24 A kind of medicine for treating facioplegia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410677978.1A CN104474173B (en) 2014-11-24 2014-11-24 A kind of medicine for treating facioplegia

Publications (2)

Publication Number Publication Date
CN104474173A true CN104474173A (en) 2015-04-01
CN104474173B CN104474173B (en) 2018-05-04

Family

ID=52748874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410677978.1A Active CN104474173B (en) 2014-11-24 2014-11-24 A kind of medicine for treating facioplegia

Country Status (1)

Country Link
CN (1) CN104474173B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056164A (en) * 2015-07-16 2015-11-18 李际文 Traditional Chinese medicinal composition for treating peripheral facial paralysis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1772107A (en) * 2005-10-27 2006-05-17 叶明伟 Chinese herbal medicine decoction for treating Qi deficiency blood stasis type senile tremor and palsy and its prepn
CN102670998A (en) * 2012-05-08 2012-09-19 成都绿迪科技有限公司 Traditional Chinese medicine for treating facial paralysis
CN102836305A (en) * 2012-08-29 2012-12-26 邵连亭 Traditional Chinese medicine formula of rehabilitation powder for facial neuritis
CN102988777A (en) * 2012-11-13 2013-03-27 于良卫 Facial paralysis capsule

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1772107A (en) * 2005-10-27 2006-05-17 叶明伟 Chinese herbal medicine decoction for treating Qi deficiency blood stasis type senile tremor and palsy and its prepn
CN102670998A (en) * 2012-05-08 2012-09-19 成都绿迪科技有限公司 Traditional Chinese medicine for treating facial paralysis
CN102836305A (en) * 2012-08-29 2012-12-26 邵连亭 Traditional Chinese medicine formula of rehabilitation powder for facial neuritis
CN102988777A (en) * 2012-11-13 2013-03-27 于良卫 Facial paralysis capsule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
封一平 等: "《用好本草 疾病不扰：家用本草养生智慧》", 28 February 2014, 科学技术文献出版社 *
陆兔林 等: "《中药炮制学》", 31 August 2014, 中国医药科技出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056164A (en) * 2015-07-16 2015-11-18 李际文 Traditional Chinese medicinal composition for treating peripheral facial paralysis

Also Published As

Publication number Publication date
CN104474173B (en) 2018-05-04

Similar Documents

Publication Publication Date Title
CN103735721B (en) A kind of Chinese medicine treating pink-eye
CN103251709B (en) External medicine nose through paste for treating rhinitis and preparation method thereof
CN104173950B (en) A kind of herbal composite for treating prostate cancer
CN104474173B (en) A kind of medicine for treating facioplegia
CN103341146B (en) Traditional Chinese medicine preparation for treating cold and dampness type chronic rhinitis
CN103520392B (en) A kind of Chinese medicine composition for the treatment of xerophthalmia and preparation method thereof
CN102327451B (en) Chinese medicinal composition for treating chronic sinusitis
CN105833034A (en) Traditional Chinese medicine composition
CN105343551A (en) Medicine composition for treating sicca syndrome and preparation method and application of medicine composition
CN104436121A (en) Medicine for treating irregular menstruation, lower abdominal distension and persistent failure to conceive
CN104523911A (en) Medicine for treating acute and chronic rhinitis
CN104173830A (en) Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof
CN104324135A (en) Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition
CN103494939A (en) Traditional Chinese medicine for treating senile habitual constipation
CN103386080B (en) Medicine composite for curing combined external head injuries in clinical nursing
CN103330896B (en) Preparation method of powder for treating postpartum nonspecific vaginitis
CN103301374B (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis
CN103316270B (en) Preparation method of powder of medicine for treating postnatal perineum mucosal lesion
CN102284035A (en) Chinese composition for treating rhinitis
CN105816613A (en) Traditional Chinese medicine composition for treating headache caused by liver-yang hyperactivity
CN104435133A (en) Medicament for reducing fever
CN104208184B (en) A kind of pharmaceutical composition treating benign prostatic hyperplasia
CN104758710A (en) External application traditional Chinese medicine used for treating allergic rhinitis
CN103735741A (en) Traditional Chinese medicinal composition for treating gout
CN103301354B (en) Preparation method of powder for treating infantile vaginitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant